Table 2.
Classification of patients into high or medium/low adherence per group, at baseline, 4 and 8 months
| Control group (n = 227) |
Empowerment group (n = 230) |
p value | |
|---|---|---|---|
| Baseline | |||
| High adherence | 130 (57.3) | 124 (53.9) | 0.470 |
| Medium/low adherence | 97 (42.7) | 106 (46.1) | |
| 4 months | |||
| High adherence | 135 (61.1) | 157 (70.7) | 0.032 |
| Medium/low adherence | 86 (38.9) | 65 (29.3) | |
| 8 months | |||
| High adherence | 144 (65.8) | 157 (72.7) | 0.117 |
| Medium/low adherence | 75 (34.2) | 59 (27.3) | |
All data are n (%). Patients were classified into high or medium/low adherence subgroups by means of their baseline MMAS-4 score (high adherence, MMAS-4 score 4; medium/low adherence, MMAS-4 score 0 to < 3). p values are for control versus empowerment group comparison
MMAS-4 four-item Morisky Medication Adherence Scale, n number of patients in specified group